CICS-UBI - Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal.
CICS-UBI - Centro de Investigação em Ciências da Saúde, Universidade da Beira Interior, Av. Infante D. Henrique, 6200-506 Covilhã, Portugal.
Drug Discov Today. 2019 Oct;24(10):2044-2057. doi: 10.1016/j.drudis.2019.07.011. Epub 2019 Aug 6.
Cervical cancer is the fourth most common cancer among women worldwide and its development is mainly associated with human papillomavirus infection, a highly sexually transmissible virus. The expression of E6 and E7 viral oncoproteins deregulates cell repairing mechanisms through impairment of tumor suppressor protein functions, such as p53 or retinoblastoma protein. Although the implementation of new preventive vaccines has decreased the infection rate and cervical cancer progression, there are still many women who are affected by this pathology. Nowadays, the main treatment often requires the use of invasive techniques. From well-established strategies, like DNA vaccines and gene therapy, to innovative gene silencing technologies; different methodologies are currently under scrutiny that target the E6 and E7 oncoproteins and/or their modes of action.
宫颈癌是全球女性中第四常见的癌症，其发展主要与人类乳头瘤病毒（HPV）感染有关，HPV 是一种高度性传播的病毒。病毒致癌蛋白 E6 和 E7 的表达通过破坏肿瘤抑制蛋白（如 p53 或视网膜母细胞瘤蛋白）的功能，使细胞修复机制失调。尽管新的预防性疫苗的实施降低了感染率和宫颈癌的进展，但仍有许多女性受到这种疾病的影响。如今，主要的治疗方法通常需要使用侵入性技术。从成熟的策略，如 DNA 疫苗和基因治疗，到创新的基因沉默技术；目前正在研究针对 E6 和 E7 致癌蛋白及其作用模式的不同方法。
